Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits.

Abstract

PURPOSE:

To determine whether a new cyclic GMP analog, 2'-O-(4-benzoyl)benzoylguanosine 3',5' cyclic monophosphate (BB-cGMP), significantly reduces intraocular pressure in either normotensive or hypertensive eyes of rabbits.

METHODS:

Intraocular pressure of normal adult rabbits and/or rabbits with alpha-chymotrypsin-induced ocular hypertension was measured after topical application of BB-cGMP for up to 72 hours after treatment.

RESULTS:

Data indicate that topical application of solutions containing BB-cGMP can significantly reduce intraocular pressure in normotensive eyes and, to a greater extent, hypertensive eyes for periods up to 12 hours for a single dose.

CONCLUSIONS:

BB-cGMP holds interest both as a clinical agent in the management of intraocular pressure and for in vitro biochemical studies on the regulation of intraocular pressure.

• Authors: P J Stein, J W Clack
• Journal: Investigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 35 Issue 6 Pg. 2765-8 (May 1994) ISSN: 0146-0404 [Print] United States
• PMID: 8188470 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Ophthalmic Solutions
• Phosphodiesterase Inhibitors
• 2'-O-(4-benzoylbenzoyl)guanosine cyclic 3',5'-monophosphate
• Chymotrypsin
• Cyclic GMP

Topics

• Administration, Topical
• Animals
• Chymotrypsin
• Cyclic GMP (administration & dosage, analogs & derivatives, chemical synthesis, pharmacology)
• Intraocular Pressure (drug effects)
• Ocular Hypertension (chemically induced, drug therapy)
• Ophthalmic Solutions
• Phosphodiesterase Inhibitors (administration & dosage, chemical synthesis, pharmacology)
• Rabbits
• Tonometry, Ocular